Sung-Soo Park
IMiD treatment(Sung-Soo Park)은 FRα 표적 세포·유전자 치료로, Multiple Myeloma, Relapsed; Multiple Myeloma (MM) 영역에서 개발·상용화 중입니다. 작용기전: that likely involves a tightly coordinated regulation of CRBN with endothelial cell targets and highlight the need to further elucidate the mechanism(s), which could include cerebl. 전임상 단계입니다. 대표 임상 효능: ORR 26.2% (ClinicalTrials.gov NCT02336815). 차별점: first-in-class IRAK4 heterobifunctional degrader that utilizes cereblon (CRBN) for E3 ligase recruitment and was rationally designed t.
FRα
Multiple Myeloma, Relapsed; Multiple Myeloma (MM)
Recruiting
bispecific antibodies, and chimeric antigen receptor T cells)
first-in-class IRAK4 heterobifunctional degrader that utilizes cereblon (CRBN) for E3 ligase recruitment and was rationally designed t
that likely involves a tightly coordinated regulation of CRBN with endothelial cell targets and highlight the need to further elucidate the mechanism(s), which could include cereblon-independent pathways, through which
immune-mediated inflammatory diseases
apoptosis, which was associated with decreased IRF4, c-Myc, and phosphorylated STAT3 levels as well as enhanced SOCS3 expression
biomarkers of Mtb burden or Mtb clearance in patients with different TB status and different risk to develop
resistance to traditional IMiDs has become more prevalent, creating an urgent need for next-generation cereblon E3 ligase modulators
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Sung-Soo Park
IMiD treatment(Sung-Soo Park)은 FRα 표적 세포·유전자 치료로, Multiple Myeloma, Relapsed; Multiple Myeloma (MM) 영역에서 개발·상용화 중입니다. 작용기전: that likely involves a tightly coordinated regulation of CRBN with endothelial cell targets and highlight the need to further elucidate the mechanism(s), which could include cerebl. 전임상 단계입니다. 대표 임상 효능: ORR 26.2% (ClinicalTrials.gov NCT02336815). 차별점: first-in-class IRAK4 heterobifunctional degrader that utilizes cereblon (CRBN) for E3 ligase recruitment and was rationally designed t.
FRα
Multiple Myeloma, Relapsed; Multiple Myeloma (MM)
Recruiting
bispecific antibodies, and chimeric antigen receptor T cells)
first-in-class IRAK4 heterobifunctional degrader that utilizes cereblon (CRBN) for E3 ligase recruitment and was rationally designed t
that likely involves a tightly coordinated regulation of CRBN with endothelial cell targets and highlight the need to further elucidate the mechanism(s), which could include cereblon-independent pathways, through which
immune-mediated inflammatory diseases
apoptosis, which was associated with decreased IRF4, c-Myc, and phosphorylated STAT3 levels as well as enhanced SOCS3 expression
biomarkers of Mtb burden or Mtb clearance in patients with different TB status and different risk to develop
resistance to traditional IMiDs has become more prevalent, creating an urgent need for next-generation cereblon E3 ligase modulators
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.